Janssen announced the extension of the Ministry of health indications for the use of ustekinumab, he is now approved for the treatment of active ulcerative colitis moderate to severe in adult patients with inadequate response, loss of response or intolerance to standard or biologic therapy, or have medical contraindications to such treatment. Ustekinumab is the first genetically engineered biological drug affecting interleukins Il12 and Ил23 playing a key role in inflammatory and immune reactions observed in immune-mediated diseases such as ulcerative colitis and Crohn’s disease (for this indication the drug was registered in 2019).
In patients with ulcerative colitis as a result of therapy ustekinumab noted achieving and maintaining remission without the use of steroids, achieving histo-endoscopic remission (healing of the intestinal mucosa), a statistically significant decrease in levels of inflammation markers, including C-reactive protein and faecal calprotectin, improving the quality of life. Patients receiving the drug for 44 weeks achieved and maintained the reduction in serum concentrations of TNF-a and IL-17A, is a proinflammatory cytokines, Il12 and adjustable Ил23 (comparison was made with placebo).
Ulcerative colitis is a serious chronic immune-mediated inflammatory disease of the large intestine. The symptoms can vary, but usually include tenesmus, diarrhea, blood in the stool, weight loss. These symptoms can be prolonged and debilitating, causing patients embarrassment and discomfort. The disease is chronic and progressive nature characterized by the development of complications such as intestinal bleeding, toxic dilatation and perforation of the colon and colorectal cancer.